Healthcare systems face mounting pressure to justify expensive Alzheimer's treatments as two FDA-approved anti-amyloid drugs compete for coverage decisions. The stakes are particularly high given Medicare's broader coverage of lecanemab compared to the restricted access imposed on aducanumab.
A comprehensive economic modeling study reveals lecanemab delivers superior value compared to aducanumab in treating early Alzheimer's disease. Using a five-state Markov model spanning lifetime horizons, researchers calculated an incremental cost-effectiveness ratio of $121,678 per quality-adjusted life-year gained when comparing lecanemab to aducanumab. While lecanemab costs approximately $30,000 more per patient, it generates an additional 0.25 quality-adjusted life-years over a lifetime.
This analysis arrives at a critical juncture for Alzheimer's care. Both drugs target amyloid-beta plaques but faced dramatically different regulatory and coverage pathways. Aducanumab's controversial approval led to Medicare restrictions, while lecanemab received traditional FDA approval and broader Medicare access in 2023. The indirect comparison methodology was necessary due to the absence of head-to-head clinical trials between these competing therapies.
The $121,678 cost-effectiveness ratio falls within commonly accepted willingness-to-pay thresholds for healthcare interventions, though it represents a significant investment for marginal gains. This economic evidence may influence coverage decisions and treatment guidelines, particularly as healthcare systems grapple with resource allocation for neurological conditions with limited therapeutic options. The findings suggest lecanemab offers incrementally better value, though both treatments remain expensive interventions for modest clinical benefits.